Company & Sponsor Intelligence
HealthPartners Institute
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting1
Completed0
Countries1
Therapeutic footprint
alzheimersparkinsonsunclassified
Indexed studies
NCT06285448Feasibility of Lecanemab Registry and Clinical Outcome Measures
alzheimers · United StatesENROLLING_BY_INVITATION
alzheimers · United StatesENROLLING_BY_INVITATION
NCT06999330TMS in Anxiety-Parkinson's Disease
parkinsons · United StatesNA
parkinsons · United StatesNA
NCT02503501Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
NCT07120386Irrigating vs Traditional Negative Pressure Wound Therapy to Treat Necrotizing Soft Tissue Infections
unclassified · United StatesNA
unclassified · United StatesNA
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →